Sugi Predict

Sugi Predict / Compounds / SCHEMBL855306

SCHEMBL855306

SCHEMBL855306

O=C(O)CCCN1CCCC1=O

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.50
▸ KMT2A Q03164 4/20 0.49
▸ CYP1A2 P05177 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ RAB9A P51151 3/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ POLB P06746 1/20 0.43
▸ ADRA1B P35368 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2944990 0.95 TSHR (0.49) TSHRKMT2ARAB9ANPC1MEN1
SCHEMBL1627525 0.95 CYP1A2 (0.52) TSHRKMT2ACYP1A2MAPK1SMN1; SMN2
SCHEMBL19513822 0.93 TSHR (0.47) TSHRKMT2ARAB9ANPC1MEN1
SCHEMBL9151143 0.93 TSHR (0.47) TSHRKMT2ARAB9ANPC1MEN1
SCHEMBL7416853 0.93 TSHR (0.47) TSHRKMT2ARAB9ANPC1MEN1
SCHEMBL19513862 0.93 TSHR (0.47) TSHRKMT2ARAB9ANPC1MEN1
SCHEMBL443220 0.89 TSHR (0.53) TSHRKMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL7103779 0.86 KMT2A (0.47) TSHRKMT2ACYP1A2MAPK1SMN1; SMN2
SCHEMBL4575280 0.85 TSHR (0.65) TSHRKMT2AMAPK1RAB9ANPC1
SCHEMBL805268 0.84 KMT2A (0.51) TSHRKMT2ASMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109867679-B Preparation method of piricaconide hydrochloride intermediate 杭州瀚康生物医药科技有限公司 2021-11-30 — — CN claimed
EP-2349335-B1 LEVETIRACETAM IMMUNOASSAYS ARK DIAGNOSTICS INC (US) 2013-08-07 — — EP claimed
US-8168756-B2 Levetiracetam immunoassays ARK DIAGNOSTICS, INC. (US) 2012-05-01 — — US claimed
EP-2349335-A1 LEVETIRACETAM IMMUNOASSAYS ARK Diagnostics, Inc. (US) 2011-08-03 — — EP claimed
US-20100173427-A1 LEVETIRACETAM IMMUNOASSAYS ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT 2010-07-08 — — US claimed
WO-2010048423-A1 LEVETIRACETAM IMMUNOASSAYS ARK DIAGNOSTICS, INC. (US) 2010-04-29 — — WO claimed
US-12599662-B2 Methods and compositions for treating cancers INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2026-04-14 — — US disclosed
US-12203938-B2 Levetiracetam immunoassays ARK DIAGNOSTICS, INC. (US) 2025-01-21 — — US disclosed
CN-116459225-B Alagox sodium tablet and preparation process thereof 东莞市金美济药业有限公司 2023-11-10 — — CN disclosed
CN-116459225-A Alagox sodium tablet and preparation process thereof 东莞市金美济药业有限公司 2023-07-21 — — CN disclosed
US-20220357331-A1 Levetiracetam Immunoassays ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT 2022-11-10 — — US disclosed
US-11231424-B2 Levetiracetam immunoassays ARK DIAGNOSTICS, INC. (US) 2022-01-25 — — US disclosed
US-20210236633-A1 METHODS AND COMPOSITIONS FOR TREATING CANCERS UNIVERSITÉ PARIS CITÉ (FR) 2021-08-05 — — US disclosed
US-5110945-A 1-azoniabicyclo[3.3.0]oct-1(5)-ene salt derivatives and process for the preparation of the same SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1992-05-05 — — US disclosed
EP-0431605-A2 1-Azabicyclo[m.n.O]alkane derivatives, their salts and process for preparing them SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1991-06-12 — — EP disclosed
US-4985569-A Pyrrolizine derivative and its manufacture SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1991-01-15 — — US disclosed
US-4897495-A Process for the preparation of pyrrolizine derivatives SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1990-01-30 — — US disclosed
CN-1038812-A Pyrrolizine derivative and preparation method thereof SANWA KAGAKU KENKYUSHO CO (JP) 1990-01-17 — — CN disclosed
EP-0345711-A2 Process for the preparation of pyrrolizine derivatives SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1989-12-13 — — EP disclosed
EP-0345712-A1 Pyrrolizine derivate and its manufacture SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1989-12-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12203938-B2 Levetiracetam immunoassays GABRG1, GABRA6, LY96 TSHR 1703/4885KMT2A 1674/4885CYP1A2 3221/4885
US-20220357331-A1 Levetiracetam Immunoassays GABRG1, GABRA6, LY96 TSHR 1703/4885KMT2A 1674/4885CYP1A2 3221/4885
US-20210236633-A1 METHODS AND COMPOSITIONS FOR TREATING CANCERS TLR3, TLR7, TLR6 TSHR 2011/4885KMT2A 177/4885CYP1A2 3198/4885
US-11231424-B2 Levetiracetam immunoassays GABRG1, GABRA6, LY96 TSHR 1703/4885KMT2A 1674/4885CYP1A2 3221/4885
US-12599662-B2 Methods and compositions for treating cancers TLR3, TLR7, TLR9 TSHR 754/4885KMT2A 151/4885CYP1A2 3819/4885
US-20100173427-A1 LEVETIRACETAM IMMUNOASSAYS GABRG1, GABRA6, LY96 TSHR 1703/4885KMT2A 1674/4885CYP1A2 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.